Tailored Cancer Therapy: Overcoming TRAIL Resistance in Patients
TRAIL has recently emerged as a novel potential anticancer agent. However, cancer cells are in specific patients resistant to TRAIL induced apoptosis. Therefore the efficacy of chemotherapy for treatment of CLL, MCL, HNSCC, bladder or prostate carci-noma is often limited due to resistance to TRAIL induced apoptosis. The technology provides a method for identification of these non-responders. Moreover, a polynucleotide encoding the modified TRAIL can serve as drug against such cancer diseases of this specific patient subgroup.
Further Information: PDF
Deutsches Krebsforschungszentrum DKfZ
Phone: +49-6221-422958
Contact
Regina Otto
